Related references
Note: Only part of the references are listed.Visceral-to-subcutaneous fat ratio is a possible prognostic factor for type 1 endometrial cancer
Michiko Wada et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2022)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
High Visceral Adipose Tissue Density Correlates With Unfavorable Outcomes in Patients With Intermediate-Stage Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
Qiang Li et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
LRP1B Expression as a Putative Predictor of Response to Pegylated Liposomal Doxorubicin Treatment in Ovarian Cancer
Isabel J. Dionisio de Sousa et al.
PATHOBIOLOGY (2021)
Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m2 versus 40 mg/m2 in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial
Takashi Motohashi et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2021)
Low-grade serous ovarian cancer: State of the science
Brian Slomovitz et al.
GYNECOLOGIC ONCOLOGY (2020)
TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers
Eleonora Ghisoni et al.
JOURNAL OF OVARIAN RESEARCH (2019)
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy
Claudia Omarini et al.
CANCER MANAGEMENT AND RESEARCH (2019)
Adipocytes promote breast cancer resistance to chemotherapy, a process amplified by obesity: role of the major vault protein(MVP)
Camille Lehuede et al.
BREAST CANCER RESEARCH (2019)
Real-World Management of Trabectedin/Pegylated Liposomal Doxorubicin in Platinum-Sensitive Recurrent Ovarian Cancer Patients A National Survey
Gabriella Ferrandina et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2017)
Impact of Recurrence of Ovarian Cancer on Quality of Life and Outlook for the Future
Nicoletta Colombo et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2017)
Patterns of Recurrence and Clinical Outcome of Patients With Stage IIIC to Stage IV Epithelial Ovarian Cancer in Complete Response After Primary Debulking Surgery Plus Chemotherapy or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery An Italian Multicenter Retrospective Study
Angiolo Gadducci et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2017)
A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer
Bryan Oronsky et al.
MEDICAL ONCOLOGY (2017)
Adipocytes Sequester and Metabolize the Chemotherapeutic Daunorubicin
Xia Sheng et al.
MOLECULAR CANCER RESEARCH (2017)
Impact of body fat distribution on neoadjuvant chemotherapy outcomes in advanced breast cancer patients
Toshiaki Iwase et al.
CANCER MEDICINE (2016)
Role of aggressive surgical cytoreduction in advanced ovarian cancer
Suk-Joon Chang et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2015)
Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma
Naoto Fujiwara et al.
JOURNAL OF HEPATOLOGY (2015)
Increased visceral to subcutaneous fat ratio is associated with decreased overall survival in patients with metastatic melanoma receiving anti-angiogenic therapy
Valerie P. Grignol et al.
SURGICAL ONCOLOGY-OXFORD (2015)
Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer
Katrina N. Slaughter et al.
GYNECOLOGIC ONCOLOGY (2014)
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. A. Ledermann et al.
ANNALS OF ONCOLOGY (2013)
Optimal first-line treatment in ovarian cancer
F. A. Raja et al.
ANNALS OF ONCOLOGY (2012)
Patient-reported outcomes in relapsed ovarian cancer: Results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD Alone
Carolyn N. Krasner et al.
GYNECOLOGIC ONCOLOGY (2012)
Serum level of adiponectin and the risk of liver cancer development in chronic Hepatitis C patients
Toru Arano et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Visceral Fat Area as a New Independent Predictive Factor of Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Antiangiogenic Agents
Sylvain Ladoire et al.
ONCOLOGIST (2011)
Ovarian Cancer
Kathleen R. Cho et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Visceral obesity may affect oncologic outcome in patients with colorectal cancer
Hyeong-Gon Moon et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
Angiogenic factors are elevated in overweight and obese individuals
JV Silha et al.
INTERNATIONAL JOURNAL OF OBESITY (2005)
Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects
S Miyazawa-Hoshimoto et al.
DIABETOLOGIA (2003)
Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: A retrospective comparative study of single-agent dosages
PG Rose et al.
GYNECOLOGIC ONCOLOGY (2001)
The clinical utility of liposomal doxorubicin in recurrent ovarian cancer
SM Campos et al.
GYNECOLOGIC ONCOLOGY (2001)
Share Paper
